EP3493816A1 - Zusammensetzung zur behandlung von veisalgia - Google Patents
Zusammensetzung zur behandlung von veisalgiaInfo
- Publication number
- EP3493816A1 EP3493816A1 EP17749180.0A EP17749180A EP3493816A1 EP 3493816 A1 EP3493816 A1 EP 3493816A1 EP 17749180 A EP17749180 A EP 17749180A EP 3493816 A1 EP3493816 A1 EP 3493816A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- group
- compound
- acid
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 235000000346 sugar Nutrition 0.000 claims abstract description 38
- 230000000202 analgesic effect Effects 0.000 claims abstract description 35
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 28
- 239000011707 mineral Chemical class 0.000 claims abstract description 28
- 235000010755 mineral Nutrition 0.000 claims abstract description 28
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 27
- 239000011573 trace mineral Substances 0.000 claims abstract description 27
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 27
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 23
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 19
- 230000003915 cell function Effects 0.000 claims abstract description 18
- 238000001784 detoxification Methods 0.000 claims abstract description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011724 folic acid Substances 0.000 claims abstract description 16
- 229960000304 folic acid Drugs 0.000 claims abstract description 16
- 235000019152 folic acid Nutrition 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract description 10
- 229930013930 alkaloid Natural products 0.000 claims abstract description 9
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 39
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 38
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 34
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 34
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 30
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 28
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 25
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 23
- 239000004201 L-cysteine Substances 0.000 claims description 20
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- 235000013878 L-cysteine Nutrition 0.000 claims description 17
- 239000001095 magnesium carbonate Substances 0.000 claims description 17
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 16
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 16
- 229960004441 tyrosine Drugs 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 14
- 229930091371 Fructose Natural products 0.000 claims description 14
- 239000005715 Fructose Substances 0.000 claims description 14
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 14
- 108010024636 Glutathione Proteins 0.000 claims description 14
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 229960003180 glutathione Drugs 0.000 claims description 14
- 229940055726 pantothenic acid Drugs 0.000 claims description 14
- 235000019161 pantothenic acid Nutrition 0.000 claims description 14
- 239000011713 pantothenic acid Substances 0.000 claims description 14
- 239000001103 potassium chloride Substances 0.000 claims description 14
- 235000011164 potassium chloride Nutrition 0.000 claims description 14
- 235000008160 pyridoxine Nutrition 0.000 claims description 14
- 239000011677 pyridoxine Substances 0.000 claims description 14
- 239000011669 selenium Substances 0.000 claims description 14
- 229910052711 selenium Inorganic materials 0.000 claims description 14
- 229940011671 vitamin b6 Drugs 0.000 claims description 14
- 239000011701 zinc Substances 0.000 claims description 14
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 13
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 13
- 229930182816 L-glutamine Natural products 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 229960002477 riboflavin Drugs 0.000 claims description 13
- 235000019192 riboflavin Nutrition 0.000 claims description 13
- 239000002151 riboflavin Substances 0.000 claims description 13
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 12
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 11
- 239000007938 effervescent tablet Substances 0.000 claims description 11
- 229960003966 nicotinamide Drugs 0.000 claims description 11
- 235000005152 nicotinamide Nutrition 0.000 claims description 11
- 239000011570 nicotinamide Substances 0.000 claims description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960001948 caffeine Drugs 0.000 claims description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 9
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 9
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 9
- 229960004874 choline bitartrate Drugs 0.000 claims description 9
- 229960005190 phenylalanine Drugs 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 8
- 229940069428 antacid Drugs 0.000 claims description 8
- 239000003159 antacid agent Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 239000011733 molybdenum Substances 0.000 claims description 8
- 229910052750 molybdenum Inorganic materials 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 235000019157 thiamine Nutrition 0.000 claims description 8
- 239000011721 thiamine Substances 0.000 claims description 8
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 7
- 230000001458 anti-acid effect Effects 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- 229910052748 manganese Inorganic materials 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 7
- 229930003799 tocopherol Natural products 0.000 claims description 7
- 229960001295 tocopherol Drugs 0.000 claims description 7
- 235000010384 tocopherol Nutrition 0.000 claims description 7
- 239000011732 tocopherol Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 235000010841 Silybum marianum Nutrition 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- 244000272459 Silybum marianum Species 0.000 claims description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 230000008093 supporting effect Effects 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- 229960001419 fenoprofen Drugs 0.000 claims description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 229960002905 tolfenamic acid Drugs 0.000 claims description 3
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002535 acidifier Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960003464 mefenamic acid Drugs 0.000 claims description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- 241000235070 Saccharomyces Species 0.000 claims 3
- 229940095602 acidifiers Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 235000019441 ethanol Nutrition 0.000 description 46
- 208000024891 symptom Diseases 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 229930003270 Vitamin B Natural products 0.000 description 15
- 235000019156 vitamin B Nutrition 0.000 description 15
- 239000011720 vitamin B Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 10
- 229930003268 Vitamin C Natural products 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 235000019154 vitamin C Nutrition 0.000 description 10
- 239000011718 vitamin C Substances 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229960003237 betaine Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- -1 fructose dextrose Chemical class 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003257 choline citrate Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003403 betaine hydrochloride Drugs 0.000 description 1
- VYMUGTALCSPLDM-UHFFFAOYSA-L carbasalate calcium Chemical group [Ca+2].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O VYMUGTALCSPLDM-UHFFFAOYSA-L 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004788 neurological cell Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- composition for the treatment of Veisalgia Composition for the treatment of Veisalgia
- the invention relates to a composition for use in the therapy of Veisalgia, a therapy kit for use in the treatment of Veisalgia and an analgesic for the treatment of Veisalgia according to the preambles of the independent claims.
- Veisalgia is the medical name for alcohol intoxication. It is often associated with a variety of symptoms, such as headache, nausea, dizziness, Schlaflo ⁇ stechnik, dehydration and fatigue. The causes of this Sympto ⁇ me are very complex and not all details of the body ablau ⁇ fenden processes are clarified. But it still maintains some essential processes that lead to the symptoms of Veisalgia, ⁇ identifi ed are. For example, dehydration and demineralization during heavy drinking contribute to the symptoms. This factor is further reinforced by the fact that those affected often fail to counteract the lack of liquid by the supply of non-alcoholic beverages. Further
- compositions which are said to at least partially alleviate the symptoms.
- US 3,829,569 be ⁇ writes, for example, a composition with six essenti- rush ingredients: an analgesic, an antidepressant, a mild stomach medicine, a mild anesthetic, a means of Un ⁇ SUPPORTING metabolism as well as a remedy for Kochklae ⁇ tion.
- the agent is administered in the form of two capsules to be taken simultaneously, both capsules comprising an analgesic.
- the division into two capsules is due to the high dosage of the individual components.
- the dosage given in US Pat. No. 3,829,569 is intended to significantly alleviate the symptoms of Veisalgia. It has been shown that this dosage form poses significant health risks. The deficiency symptoms which contribute to the development of Veisalgia can not be counteracted thereby.
- compositions for the treatment of the above-mentioned symptoms are also described in WO 87/01285, in which case an analgesic is also administered in each case.
- the composition should be safe in the application.
- the invention relates to a composition for use in the therapy of Veisalgia.
- the composition comprises at least one sugar or sugar compound.
- the sugar or sugar compound are preferential, from the group: fructose, sucrose and glucose, ⁇ be selected.
- a preferred glucose is D-glucose, also known as dextrose.
- compounds of various sugars, such as fructose dextrose are conceivable.
- hypoglycaemia can be avoided.
- Hypoglycaemia can lead to a series of negative processes that promote the development of symptoms of Veisalgia, such as fatigue, weakness and headache. These symptoms are counteracted by the sugar intake as far as possible.
- the composition includes mineral salts.
- Preferred Mineralsal ⁇ ze in particular a potassium salt, a sodium salt, a magnesium salt and a calcium salt.
- Ver ⁇ application of potassium chloride, sodium citrate, magnesium and / or calcium carbonate.
- This Minera ⁇ lien are particularly important in relation to the nervous system and the muscular system and therefore have the appearance of numerous Veisalgia symptoms counter also.
- various salts of a mineral in the composition for example magnesium carbonate, magnesium hydroxide and magnesium oxide.
- the acid-binding Properties and the bioavailability of a mineral ver ⁇ strengthens.
- the composition comprises at least one compound to the cell contactor.
- a compound may in particular be an antioxidant. It has proved advantageous to select at least one anti ⁇ oxidant selected from the group consisting of ascorbic acid, tocopherol, a glutathione precursor, glutathione and / or Phospahtidylserin. Alternatively, it is also possible to use a combination of different antioxidants. Suitable glutathione precursors include, for example, N-acyl-L-cysteine, L-cysteine and / or glutamic acid. Antioxidants are characterized by their properties as radical scavengers, reducing agents and pH-regulating properties. Particularly advantageous is a combination of ascorbic acid
- the composition further comprises at least one compound for promoting cellular function.
- the compound is preferably selected from the group: nicotinamide (vitamin B3), nicotinic acid, riboflavin (vitamin B 2 ), pantothenic acid (vitamin B 5 ),
- ⁇ DERS Pyridoxine (Vitamin ⁇ ), Thiamin (Vitamin Bi), Vitamin B 12 .
- ⁇ DERS particular preferred is a combination of two or more compounds which ⁇ ser. These compounds support the breakdown of alcohol in the cells. Thiamine and vitamin B 12 contribute to neurocellular protection.
- the composition comprises at least one compound for promoting detoxification.
- This connection is particularly especially selected from the group: Betaine, Silybum marianum (milk thistle), Zingiberis rhizoma (ginger root), activated carbon, L-cysteine.
- Betaine Silybum marianum (milk thistle)
- Zingiberis rhizoma ginger root
- activated carbon L-cysteine.
- the composition has at least one neurotransmitter.
- the neurotransmitter is preferably selected from the group: L-tyrosine, L-tryptophan, L-phenylalanine, LD-phenylalanine (racemat), L-glutamine, dihydromyricetines, choline bitartrate, citrate.
- the term "neurotransmitter” includes the precursors of neurotransmitters, ie substances which can be converted into the corresponding neurotransmitter in the human body. So L-tryptophan can be converted into dopamine to serotonin and L-Tyrosine. These compounds have a schensaufhel ⁇ .
- the composition comprises at least one trace element, in particular ⁇ sondere selenium and / or zinc;.. and folic acid as particularly before ⁇ geous the use of all three trace elements has he reported ⁇
- the composition may contain other trace elements are added, such as biotin Manganese and / or Molybdenum Trace elements are essential for maintaining a variety of processes in the human body.
- composition may be desirable to add to the composition a stimulating alkaloid, especially caffeine. This prevents fatigue symptoms in particular.
- the composition contains no analgesic.
- Such a composition for use in the treatment of Veisalgia has the advantage of being as ⁇ supplies the nutrients the human body, which are lost due to alcohol consumption or advertising because of its needs in an increased amount to, thereby reducing the symptoms of poisoning phenomenon.
- Nutrients are generally understood to mean compounds for the maintenance of health-relevant biological processes in the human body, in particular the compounds mentioned here.
- This composition has also back from the advantage that it can be taken preventively before or during alcohol consumption because it contains no analgesic and side effects with alcohol therefore not occurring defects ⁇ th.
- the composition may comprise at least one further additive being selected from the group ⁇ : flavor, dyes, disintegrating agents, acidulants, included.
- disintegrating substances are to be understood, which is improving the subsequent disintegration of the tablet ⁇ fibers.
- Preference is given to using sodium bicarbonate and / or sodium carbonate.
- corn and potato starch ⁇ ke or polyvinylpyrrolidone are also conceivable.
- Citric acid is preferably used as the acidifier. It can also be used multiple ad ⁇ -propellant additives. Such additives can on the one hand simplify the handling of the tablet and on the other hand improve the appearance and taste perception.
- the composition is preferably in the form of a tablet, capsule, suspension, soluble powder, ready-to-drink beverage or depot formulation.
- the use of the composition in the form of effervescent tablets or soluble powders has proven particularly advantageous. ver exposed.
- the effervescent tablet or the powder are preferably dissolved in 300 to 400 mL of water for ingestion.
- composition thus present can be taken particularly easily and quickly.
- the dissolution in water has the additional advantage that a liquid present deficiency is alsogli ⁇ chen.
- the invention further relates to a composition for use in the therapy of Veisalgia.
- the composition comprises
- At least one sugar or a sugar compound in particular selected from the group: fructose, sucrose and glucose;
- - mineral salts in particular, a potassium salt, a sodium salt, a magnesium salt and a calcium salt; and very particularly preferably potassium chloride, sodium citrate, magnesium carbonate and / or calcium carbonate;
- At least one compound for cell protection in particular an antioxidant selected from the group: ascorbic acid, tocopherol, a glutathione precursor, in particular N-acyl-L-cysteine and / or L-cysteine; Glutathione and / or phosphatidylserine;
- an antioxidant selected from the group: ascorbic acid, tocopherol, a glutathione precursor, in particular N-acyl-L-cysteine and / or L-cysteine; Glutathione and / or phosphatidylserine;
- At least one compound for supporting cell function in particular selected from the group: nicotinamide, nicotinic acid, riboflavin, pantothenic acid, pyridoxine, thiamine, vitamin B12;
- At least one compound to promote detoxification in particular betaine, silymum marianum, zingiberis rhizoma, activated charcoal, L-cysteine;
- - at least one neurotransmitter in particular, be ⁇ selected from the group: L-tyrosine, L-tryptophan, L-phenylalanine, LD-phenylalanine (racemate), L-glutamine, Dihydromyricetine; Choline bitartrate, citrate; at least one trace element, in particular selenium and / or zinc;
- trace elements in particular biotin, manganese and / or molybdenum;
- a stimulating alkaloid in particular Kof ⁇ fine;
- the Verabrei ⁇ monitoring the composition of ER within 12 hours followed by at least once immediately after alcohol consumption, and two more times. Between the revenue a pause of at least ⁇ least two hours should be. The period from the first intake to the third intake should therefore be at least six hours and no more than 12 hours.
- This dosage has the advantage that the therapeutic effect also persists when, due to pharmacokinetic properties and biological half-life, premature lowering of the nutrient concentration occurs.
- the composition may be at least once prior to additional alcohol consumption or during consumption of alcohol administered ⁇ the. Alternatively, it is also possible to reduce the composition at least at least once before drinking alcohol and at least once during alcohol consumption.
- the composition can thus be taken already preventively or concomitantly. Consumption before drinking ensures that the nutrient reserves in the body are filled up. The intake during the alcohol consumption ensures that the nutrient concentration does not drop to a health-endangering level. The complaints caused by Veisalgia are less pronounced. The absence of an analgesic no side effects occur, wel ⁇ che are on the interaction of an analgesic with alcohol ⁇ recirculate.
- the composition may be co-administered at least 4 hours after alcohol consumption with an analgesic. After 4 hours, the alcohol concentration in the blood is significantly reduced, so that the intake of an analgesic is less problematic.
- the simultaneous intake of the composition and the Analgeti ⁇ cum has the advantage that the therapeutic effect is increased.
- composition can be any organic compound.
- sugar or sugar compounds preferably 12 to 20 g and most preferably 16 to 18 g; 100 to 1500 mg of the mineral salts, preferably 400 to 1300 mg and most preferably 800 to 1100 mg; 10 to 900 mg of compounds for cell protection, preferably 50 to 300 mg and most preferably 90 to 200 mg;
- 0.5 to 7 g of the neurotransmitters preferably 3 to 7 g of the neurotransmitters, and most preferably 3 to 5 g; 1 to 30 mg of compounds to aid in cell function, preferably 15 to 30 mg, and most preferably
- biotin optional: 2 to 10 mg biotin; 1 to 6 mg of manganese; 50 to 300 mg molybdenum; and / or 20 to 100 mg of caffeine
- a combination of the individual compounds in the widest quantitative range is a preferred embodiment of the invention. This information refers to the one-time use of the composition. Overall can per treatment up to 50 g To ⁇ sugar or sugar compounds, 6 g mineral salts, 6 g of connections to the cell protection, 14 g neurotransmitters, 500 mg compounds to support cellular function, 6 g of the compounds to promote detoxification, 1 mg of folic acid and 50 mg trace elements are turned ⁇ sets.
- the individual dosages and / or compositions of the individual compounds for ingestion before, during and after alcohol consumption may be the same or vary. Preferably, the individual compounds are dosed so that they move in the range of the recommended daily dose based on the single dose or total dose. For example, the total dose of magnesium should not exceed 400 mg.
- the overdose of water-binding substances can have a laxative effect.
- the dosage of vitamin C in a single dose is preferably in the range of the recommended daily dose.
- the invention relates to a therapy kit for use in the treatment of Veisalgia.
- the therapy kit includes at least two separately administrable components.
- a first component is a composition of
- At least one sugar or a sugar compound in particular selected from the group: fructose, sucrose and glucose;
- - mineral salts in particular, a potassium salt, a sodium salt, a magnesium salt and a calcium salt; and very particularly preferably potassium chloride, sodium citrate, magnesium carbonate and / or calcium carbonate;
- At least one compound for cell protection in particular an antioxidant selected from the group: ascorbic acid, tocopherol; a glutathione precursor, especially N-acyl-L-cysteine and / or L-cysteine; Glutathione and / or phosphatidylserine;
- an antioxidant selected from the group: ascorbic acid, tocopherol; a glutathione precursor, especially N-acyl-L-cysteine and / or L-cysteine; Glutathione and / or phosphatidylserine;
- At least one compound for supporting cell function in particular selected from the group: nicotinamide, nicotinic acid, riboflavin, pantothenic acid, pyridoxine, thiamine, vitamin B12;
- At least one compound to promote detoxification in particular betaine, silymum marianum, zingiberis rhizoma, activated charcoal, L-cysteine;
- - at least one neurotransmitter in particular, be ⁇ selected from the group: L-tyrosine, L-tryptophan, L-phenylalanine, LD-phenylalanine (racemate), L-glutamine, Dihydromyricetine; Choline bitartrate, citrate;
- At least one trace element in particular selenium and / or zinc
- trace elements in particular biotin, manganese and / or molybdenum;
- a stimulating alkaloid especially Kof ⁇ fine
- the second component is an analgesic and may alternatively also contain an antacid and / or a stimulatory alkaloid, preferably caffeine.
- composition of the first components may comprise the above-described amounts of the compounds.
- kit may comprise several unit doses of the first component and the second component, which differ in the composition of the compounds and / or dosages of the individual compounds.
- the second component may include a unique be occupied Do ⁇ tion 100 to 1000 mg of the analgesic.
- the second component may also contain 100 to 1000 mg of an antacid and / or 20 to 100 mg of a stimulatory alkaloid.
- the kit is characterized in that the composition are so ⁇ as analgesic for the treatment of Veisalgia the same time, and in sufficient amounts. But also a separate intake of the components is possible. Also, a component may be omitted if not needed.
- the treatment can be optimally adapted to the severity of the Veisalgia as well as the symptoms. It has also been found, surprisingly, that side effects of the analgesic can be minimized when the first component is administered with the analgesic almost at the same time. The first component thus has additional a positive effect on the second compo ⁇ component.
- the analgesic is preferably selected from the group: Ace ⁇ tylsalicylklare, ibuprofen, acetaminophen min Textre, fenoprofen, Mefena-, naproxen, codeine or tolfenamic acid. It has proved advantageous, well-studied and use stan ⁇ dardized analgesics. Caffeine analgesics are known and readily available. Their interactions and side effects are well documented and can therefore be taken into account within the scope of the invention in the context of standard routine measures. Commercial products which can be used in the context of the invention are, for example, Contrariti® plus or Alcacyl® Extra.
- the antacid can from the group: aluminum hydroxide, magnesium hydroxide ⁇ , calcium carbonate, magnesium carbonate or aluminum-magnesium silicate hydrate may be selected. Also a combination of different antacids is possible.
- an antacid reduces the risk of stomach hyperacidity. This may be particularly important when taking ibuprofen. Ibuprofen is known for its stomach irritant effect. At the same time the antacid can further increase the bioavailability of minerals such as Cal ⁇ zium or magnesium.
- the first and second component of the common seed can Therapiekits ⁇ or staggered in time at least 4 hours after alcohol consumption are administered.
- the first component Kom ⁇ 4 hours administered one hour later after the consumption of alcohol and the second component.
- a temporally ver ⁇ set ingestion of up to 2 hours is conceivable.
- the simultaneous intake has the advantage that the therapeutic ⁇ cal effect is improved.
- the phased intake has the advantage that a dose depending on the behan to ⁇ delnden symptoms can occur. Further co-administration or staggered administration of the components may occur at least 6 hours after alcohol consumption. This also results in an improved therapeutic effect.
- the administration of the first component may alternatively also be performed at least once before alcohol consumption and during alcohol ⁇ consumption. It is also possible that the composition is additionally administered only before alcohol consumption or only during alcohol consumption.
- the intake of the first component before drinking alcohol has the advantage that the nutrient reserves in the body can be replenished.
- the intake during the alcohol consumption reduces the
- the invention also relates to an analgesic for the treatment of
- Veisalgia by co-administration or staggered administration with a composition as described above.
- the analgesic is preferably acetylsalicylic acid, ibu- profen, acetaminophen, fenoprofen, mefenamic acid, naproxen, codeine or tolfenamic acid.
- Example 1 shows a preferred dosage for a first compo ⁇ component and a second component for a taken after Al ⁇ koholkonsum.
- Vitamin B fthiamin 1.1
- Vitamin B 3 (Nicotinamide) * * 18
- Vitamin B 5 pantothenic acid 6
- the first component in Example 1 can be taken alone, together with the second component or offset in time with the two ⁇ th component.
- the first component alone can before and / or be used during mecanicalkonsumie ⁇ tion also.
- Example 2 shows a further preferred dosage for a ers ⁇ th component and a second component.
- the first component may be taken before or directly after alcohol consumption, preferably without the second component.
- the second intake can be taken about 4 hours after drinking alcohol or after getting up (about 8 hours after drinking alcohol), preferably with the second component.
- a third dose may be given 3 hours after the second intake or after getting up (about 8 hours later).
- the third intake is just ⁇ if with the second component.
- Component 1 and 2 can be present as a therapy kit.
- Vitamin B 3 (Nicotinamide) 16
- Vitamin B 5 pantothenic acid 6
- Example 3 shows three different dosages of the individual compositions with staggered intake in alcohol consumption.
- the first dosage is preferably taken before or immediately after alcohol consumption without the second component.
- the second dose can be taken about 4 hours after alcohol consumption or after getting up (about 8 hours after drinking alcohol), preferably with a first composition of a second component.
- the third dosage may optionally be taken 3 hours after the second ingestion or after getting up (about 8 hours later), preferably with a second composition for the second component.
- the individual dosages can be present as a therapy kit comprising the three differently dosed compositions and the differently dosed analgesic.
- the composition of the individual dosages is preferably as follows: Composition of the first do [mg] composition of the second classification (1) Dosage (2)
- Sylybum marianum 250 Sylybum marianum 250
- Vitamin C 80 Vitamin C 80
- Vitamin E 12 Vitamin E 12
- Dihydromyricetines 200 dihydromyricetines 100
- Vitamin B fthiamin) 1.1 vitamin B fthiamin) 1.1
- Vitamin B 3 (Nicotinamide) 16 Vitamin B 3 (Nicotinamide) 16
- Vitamin B 5 (pantothenic acid) 6
- Vitamin B 5 (pantothenic acid) 6
- Vitamin B fthiamin 1.1
- Vitamin B 3 (Nicotinamide) 16
- Vitamin B 5 pantothenic acid 6
- Example 4 shows different dosages and Caribbeanset ⁇ requisite for the temporally staggered intake in alcohol consumption.
- the first composition and dosage is preferably taken before or after alcohol consumption without the second component.
- the second composition and dosage may be taken about 4 hours after alcohol consumption or after getting up (about 8 hours after drinking alcohol), preferably with a first composition of a second component.
- the third composition and dosage may optionally be 3 hours after the second ingestion or after getting up (about 8 hours later), preferably with a second composition for the second component.
- the individual compositions and dosages may be present as a therapy kit comprising the three differently dosed compositions and the differently composed analgesics.
- the composition of the individual dosages is preferably as follows:
- Sylybum marianum 250 Sylybum marianum 250
- Vitamin C 80 Vitamin C 80
- Vitamin E 12 Vitamin E 12
- Phosphatidylserine 200 Phosphatidylserine 200
- Lyptophan 200 L-ryptophan 100
- Vitamin B iThiamin) 1.1 Vitamin B iThiamin) 1.1
- Vitamin B 3 (nicotinamide) * * 16 Vitamin B 3 (nicotinamide) * * 16
- Vitamin B 5 (pantothenic acid) 6
- Vitamin B 5 (pantothenic acid) 6
- Vitamin B fthiamin 1.1
- Vitamin B 3 (Nicotinamide) 16
- Vitamin B 5 pantothenic acid 6
- FIG. 1 shows schematically the concentration profile of the substances present in the body as a function of a dosage of the composition according to the invention.
- the curve 3 indicates the profile of the minerals during drinking, gekennzeich ⁇ net by the time interval AB, while sleeping, labeled in ⁇ is characterized by the time interval BC, during the occurrence of Veisalgia symptoms, characterized by the time interval CD and after Veisalgia D .
- curve 4 accordingly indicates the course of the blood sugar and curve 5 shows the relative Kon ⁇ concentration of toxins in the blood.
- toxins are in particular ⁇ sondere degradation products due to alcohol metabolism, such as to understand examples game, acetaldehyde and acetate.
- a Darrei ⁇ form of the composition la is taken before the alcohol consumption A.
- the concentration of minerals 3 in the blood reaches a maximum value.
- the concentration of minerals 3 drops.
- the blood sugar value 4 increases, also due to the supply of alcoholic beverages.
- the concentration of poisons 5 continues to rise.
- the composition lb can be taken a second time.
- the composition lc is taken once more.
- the concentration of minerals 3 increases again, but falls later in the course of consumption in biological processes, in particular in connection with the degradation of toxins 5 again.
- the concentration of blood sugar 4 drops again after a short increase. Due to the metabolism of alcohol, the concentra ⁇ on increases in blood toxins 5 during sleep BC to a ma imum ⁇ value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16182785.2A EP3278793A1 (de) | 2016-08-04 | 2016-08-04 | Zusammensetzung zur behandlung von veisalgia |
PCT/EP2017/069805 WO2018024887A1 (de) | 2016-08-04 | 2017-08-04 | Zusammensetzung zur behandlung von veisalgia |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3493816A1 true EP3493816A1 (de) | 2019-06-12 |
Family
ID=56609709
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16182785.2A Withdrawn EP3278793A1 (de) | 2016-08-04 | 2016-08-04 | Zusammensetzung zur behandlung von veisalgia |
EP17749180.0A Pending EP3493816A1 (de) | 2016-08-04 | 2017-08-04 | Zusammensetzung zur behandlung von veisalgia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16182785.2A Withdrawn EP3278793A1 (de) | 2016-08-04 | 2016-08-04 | Zusammensetzung zur behandlung von veisalgia |
Country Status (7)
Country | Link |
---|---|
US (2) | US20190350888A1 (de) |
EP (2) | EP3278793A1 (de) |
KR (2) | KR20190041483A (de) |
CN (2) | CN116059220A (de) |
BR (1) | BR112019002109A2 (de) |
RU (1) | RU2757379C2 (de) |
WO (1) | WO2018024887A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018134714A1 (en) * | 2017-01-21 | 2018-07-26 | R&R Salons Pvt. Ltd. | Whitening skin care composition based on dihydromyricetin, niacinamide and a ph modifier |
GR1010117B (el) * | 2020-07-14 | 2021-11-08 | Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Διατροφικο συμπληρωμα για την απο του στοματος χορηγηση συνδυασμου διυδρομυρισετινης, χολινης και μιας ή περισσοτερων βιταμινων με αντιοξειδωτικη δραση, χρησιμων για τη φυσιολογικη λειτουργια του ηπατος |
CN112956623A (zh) * | 2021-03-05 | 2021-06-15 | 王正元 | 一种具有消除宿醉不良症状的饮料 |
WO2023016471A1 (zh) * | 2021-08-10 | 2023-02-16 | 武汉远大弘元股份有限公司 | 谷胱甘肽前体的组合物、制剂、制备方法及用途 |
FR3142665A1 (fr) * | 2022-12-02 | 2024-06-07 | Hedonist Labs | Composition effervescente |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3829569A (en) | 1967-10-27 | 1974-08-13 | Tri Kem Corp | Therapeutic composition and method for its use |
US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
GB8521275D0 (en) | 1985-08-27 | 1985-10-02 | Blass D H | Therapeutic composition |
AT411958B8 (de) * | 1998-11-19 | 2004-09-27 | Jhs Privatstiftung | Erfrischungsgetränk zur steigerung der alkohol-abbau-kapazität |
JP3672782B2 (ja) * | 1999-12-08 | 2005-07-20 | Smc株式会社 | クランプ装置 |
US20050271754A1 (en) * | 2004-06-07 | 2005-12-08 | Cochrane Patrick W | Composition for prevention or treatment of an alcohol hangover |
EP1932542A1 (de) * | 2006-12-15 | 2008-06-18 | TIMA Foundation | Antioxidantzusammensetzung und ihre Verwendung in Diabetes |
CN101766635B (zh) * | 2008-12-31 | 2012-10-10 | 克科 | 解酒醒酒组合物 |
AU2010235993A1 (en) * | 2010-10-25 | 2012-05-10 | Gillilands Island Of Health And Dreams | Hangover cure |
DE102011013224A1 (de) * | 2011-03-07 | 2012-09-13 | Roman Gerdes | Orthomolekulares Mittel gegen die Folgen von Alkoholkonsum |
CN102894436A (zh) * | 2011-07-25 | 2013-01-30 | 江西食方食坊中药食品有限公司 | 一种具有解酒作用的枳椇饮料及其制备方法 |
ES2919874T3 (es) * | 2014-09-24 | 2022-07-28 | Vital Beverages Global Inc | Composiciones y métodos para el suministro selectivo en el tubo gastrointestinal |
-
2016
- 2016-08-04 EP EP16182785.2A patent/EP3278793A1/de not_active Withdrawn
-
2017
- 2017-08-04 EP EP17749180.0A patent/EP3493816A1/de active Pending
- 2017-08-04 CN CN202310185432.3A patent/CN116059220A/zh active Pending
- 2017-08-04 US US16/322,764 patent/US20190350888A1/en not_active Abandoned
- 2017-08-04 RU RU2019105585A patent/RU2757379C2/ru active
- 2017-08-04 KR KR1020197006396A patent/KR20190041483A/ko active Application Filing
- 2017-08-04 BR BR112019002109-4A patent/BR112019002109A2/pt active Search and Examination
- 2017-08-04 CN CN201780056872.1A patent/CN109715168A/zh active Pending
- 2017-08-04 KR KR1020237041131A patent/KR20230167446A/ko not_active Application Discontinuation
- 2017-08-04 WO PCT/EP2017/069805 patent/WO2018024887A1/de unknown
-
2021
- 2021-12-10 US US17/547,635 patent/US20220096413A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2019105585A (ru) | 2020-09-04 |
US20190350888A1 (en) | 2019-11-21 |
CN109715168A (zh) | 2019-05-03 |
EP3278793A1 (de) | 2018-02-07 |
RU2757379C2 (ru) | 2021-10-14 |
KR20230167446A (ko) | 2023-12-08 |
CN116059220A (zh) | 2023-05-05 |
WO2018024887A1 (de) | 2018-02-08 |
RU2019105585A3 (de) | 2020-10-29 |
US20220096413A1 (en) | 2022-03-31 |
KR20190041483A (ko) | 2019-04-22 |
BR112019002109A2 (pt) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3493816A1 (de) | Zusammensetzung zur behandlung von veisalgia | |
EP2683373B1 (de) | Orthomolekulares mittel gegen die folgen von alkoholkonsum | |
EP2613790A1 (de) | Abführmittel enthaltend polyethylenglykol und elektrolyte | |
US10610556B2 (en) | Compositions for regulation and control of appetite | |
WO2013006982A1 (de) | Diätisches mehrkomponentensystem | |
CH712787A2 (de) | Zusammensetzung zur Behandlung von Veisalgia. | |
LU501504B1 (de) | Pulverförmiges nahrungsergänzungsmittel zur herstellung eines getränks | |
CN101574370A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101584706A (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
EP3090638A1 (de) | Nahrungsergänzung zur behandlung von vitamin-d3-mangelerscheinungen | |
US20230139125A1 (en) | Dietary supplement for improving brain performance | |
CN101474299B (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
DE102019128196A1 (de) | Präparat zur medizinischen Verwendung für die Behandlung einer Krankheit infolge Schädigung der tubulären Nierenfunktion | |
CN101461868A (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
CN101574371A (zh) | 用于降低血糖和血脂的药物组合物 | |
EP3445341A1 (de) | Verwendung von homoeriodictyol (hed) zum reduzieren der magensäuresekretions-stimulierenden wirkung von n-acetyl-4-aminophenol (paracetamol) | |
CN101574369A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101700256A (zh) | 用于降低血脂的药物组合物 | |
WO2004096200A1 (de) | Kombination aus desoxypeganin und mecamylamin zur behandlung des alkoholmissbrauches | |
CN101584737A (zh) | 用于降低血糖与血脂和治疗糖尿病的药物组合物 | |
CN101590150A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101596212A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101569651A (zh) | 用于降低血糖的药物组合物 | |
CN101669976A (zh) | 用于降低血脂的药物组合物 | |
CN101596213A (zh) | 用于降低血糖和血脂的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220224 |